title: Anaplastic thyroid carcinoma with long term survival after combined treatment: case report.
abstract: Anaplastic thyroid carcinoma (ATC) is associated with an almost uniformly rapid and lethal clinical course. ATC grows rapidly and invades surrounding tissues at an early stage. Despite surgery, chemotherapy and radiotherapy, few patients with ATC live more than 1 year follow-up diagnosis. The mean survival is reported to be only 7.2 months. Treatment of ATC is still controversial because of its rarity and advanced stage at the time of diagnosis. We report herein an unusual case of ATC, 35 year old woman. She is alive without evidence of recurrence more than 36 months after combined therapy.
authors: Gazi University Faculty of Medicine, Department of General Surgery, Ankara, Turkey. okurukahveci@yahoo.com
authors: Osman
authors: O
authors: Kurukahvecioglu
authors: Bahadir
authors: B
authors: Ege
authors: Aylar
authors: A
authors: Poyraz
authors: Ekmel
authors: E
authors: Tezel
authors: Ferit
authors: F
authors: Taneri
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D043823:Taxoids / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D043823:Taxoids; D000077143:Docetaxel